Preliminary Report - ID Mapping

Traditionally the BioGRID repository has required that all curated data map to a peer-reviewed Pubmed ID before public release. With the rapidly evolving global health crisis of COVID-19, we've decided to temporarily suspend that requirement in order to more rapidly curate publications released on platforms such as BiorXiv and provide that data to the research community. As a result, some of our download files currently require a Pubmed ID to output correctly (such as PSI-MI TAB, BioGRID TAB2, and PSI-MI XML). We recommend anyone wanting to get the most accurate download available to please use our newest TAB3 format instead.

In order to maintain compatibility, we've temporarily assigned new custom IDs in place of Pubmed IDs for each of these publications. So, if you see one of these IDs, you can use the following listing to determine the associated DOI for each.

WARNING - Please treat these papers with caution as they are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.

888800000002 10.1101/2020.03.29.20041962 Gao T (2020) Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation
888800000003 10.1101/2020.02.16.951723 Sun C (2020) SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development
888800000005 10.1101/2020.03.14.988345 Wang K (2020) SARS-CoV-2 invades host cells via a novel route: CD147-spike protein
888800000006 10.1101/2020.02.17.951848 Zhou Q (2020) Structure of dimeric full-length human ACE2 in complex with B0AT1
888800000007 10.1101/2020.02.26.964882 Jin Z (2020) Structure of Mpro from COVID-19 virus and discovery of its inhibitors [DEPRECATED PUBLICATION]
888800000008 10.1101/2020.03.29.013490 Wang C (2020) Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2
888800000009 10.1101/2020.03.25.996348 Dai W (2020) Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease
888800000010 10.1101/2020.03.15.992883 Joyce MG (2020) A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein
888800000011 10.1101/2020.03.16.993386 Gao Y (2020) Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target
888800000013 10.1101/2020.04.15.042085 Bestle D (2020) TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets
888800000018 10.1101/2020.04.19.049643 Zeng X (2020) Blocking antibodies against SARS-CoV-2 RBD isolated from a phage display antibody library using a competitive biopanning strategy
888800000020 10.1101/2020.04.22.046565 Liu Y (2020) Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals Broad Potential Host Range of SARS-CoV-2
888800000021 10.1101/2020.04.21.053017 Walker A (2020) Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases
888800000022 10.1101/2020.04.17.047498 Rosas Lemus M (2020) The crystal structure of nsp10-nsp16 heterodimer from SARS CoV-2in complex with S-adenosylmethionine
888800000025 10.1101/2020.04.29.068890 Rut W (2020) Activity profiling of SARS-CoV-2-PLpro protease provides structural framework for anti-COVID-19 drug design
888800000029 10.1101/2020.05.02.20086876 Zhang D (2020) Ultra-fast and onsite interrogation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in environmental specimens via surface enhanced Raman scattering (SERS)
888800000031 10.1101/2020.05.06.079830 Zha L (2020) Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles
888800000032 10.1101/2020.05.02.043554 Gunther S (2020) Catalytic cleavage of HEAT and subsequent covalent binding of the tetralone moiety by the SARS-CoV-2 main protease
888800000034 10.1101/2020.05.03.074914 Liu X (2020) Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection
888800000035 10.1101/2020.05.21.109157 Lui I (2020) Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity
888800000036 10.1101/2020.05.21.107870 Partridge LJ (2020) Unfractionated heparin potently inhibits the binding of SARS-CoV-2 spike protein to a human cell line
888800000037 10.1101/2020.05.13.092478 Chiodo F (2020) Novel ACE2-Independent Carbohydrate-Binding of SARS-CoV-2 Spike Protein to Host Lectins and Lung Microbiota
888800000038 10.1101/2020.05.12.091298 Seydoux E (2020) Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual
888800000040 10.1101/2020.05.12.092171 Zhou X (2020) Structure of SARS-CoV-2 main protease in the apo state reveals the inactive conformation
888800000041 10.1101/2020.06.17.156455 Stukalov A (2020) Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV
888800000042 10.1101/2020.06.05.135921 Bertoglio F (2020) SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
888800000043 10.1101/2020.06.05.135699 Moustaqil M (2020) SARS-CoV-2 proteases cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species and the search for reservoir hosts.
888800000046 10.1101/2020.06.17.158121 Cubuk J (2020) The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA
888800000050 10.1101/2020.06.07.138677 Luan X (2020) Structure Basis for Inhibition of SARS-CoV-2 by the Feline Drug GC376
888800000052 10.1101/2020.06.06.137513 Lou Y (2020) Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody libraries
888800000054 10.1101/2020.06.16.155812 Li J (2020) Crystal structure of SARS-CoV-2 main protease in complex with a Chinese herb inhibitor shikonin
888800000056 10.1101/2020.06.16.154708 Hanson QM (2020) Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay
888800000063 10.1101/2020.07.31.230730 Cao W (2020) Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction
888800000064 10.1101/2020.07.24.219857 Esparza TJ (2020) High Affinity Nanobodies Block SARS-CoV-2 Spike Receptor Binding Domain Interaction with Human Angiotensin Converting Enzyme
888800000065 10.1101/2020.07.25.221036 Shilts J (2020) No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor
888800000066 10.1101/2020.07.13.201517 Davies JP (2020) Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies
888800000067 10.1101/2020.07.31.229781 Alitongbieke G (2020) Study on beta-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2
888800000069 10.1101/2020.07.27.224089 Beasley MD (2020) Antibodies that potently inhibit or enhance SARS-CoV-2 spike protein-ACE2 interaction isolated from synthetic single-chain antibody libraries
888800000070 10.1101/2020.07.29.227462 Gao C (2020) SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors
888800000071 10.1101/2020.07.26.222026 Zheng Y (2020) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) Protein Inhibits Type I and III Interferon Production by Targeting RIG-I/MDA-5 Signaling
888800000072 10.1101/2020.07.30.229187 Shi W (2020) A dynamic regulatory interface on SARS-CoV-2 RNA polymerase
888800000075 10.1101/2020.07.15.204404 Schmidt N (2020) A direct RNA-protein interaction atlas of the SARS-CoV-2 RNA in infected human cells
888800000076 10.1101/2020.08.03.234914 Cao L (2020) De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. [DEPRECATED]
888800000078 10.1101/2020.07.17.208959 Fu Z (2020) Structural basis for the inhibition of the papain-like protease of SARS-CoV-2 by small molecules
888800000079 10.1101/2020.07.31.231282 Tee KL (2020) Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay
888800000080 10.1101/2020.07.25.220806 Temerozo JR (2020) The neuropeptides VIP and PACAP inhibit SARS-CoV-2 replication in monocytes and lung epithelial cells and decrease the production of proinflammatory cytokines in infected cells.
888800000081 10.1101/2020.08.03.234559 Addetia A (2020) SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98
888800000082 10.1101/2020.08.28.272955 Laurent E (2020) Global BioID-based SARS-CoV-2 proteins proximal interactome unveils novel ties between viral polypeptides and host factors involved in multiple COVID19-associated mechanisms
888800000083 10.1101/2020.08.20.259770 Lapointe CP (2020) Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome inhibits translation initiation
888800000084 10.1101/2020.08.16.252973 Han L (2020) SARS-CoV-2 ORF9b Antagonizes Type I and III Interferons by Targeting Multiple Components of RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING Signaling Pathways
888800000085 10.1101/2020.08.06.238915 Watson A (2020) Peptide Antidotes to SARS-CoV-2 (COVID-19)
888800000086 10.1101/2020.08.12.247767 Yang Z (2020) Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2
888800000087 10.1101/2020.08.12.246389 Risner K (2020) Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture
888800000088 10.1101/2020.08.08.238469 Schoof M (2020) An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation
888800000089 10.1101/2020.08.14.250258 Chen Y (2020) Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 main protease by tafenoquine in vitro
888800000090 10.1101/2020.08.09.242917 Thepaut M (2020) DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist
888800000093 10.1101/2020.08.18.256776 Andres AD (2020) SARS-CoV-2 ORF9c Is a Membrane-Associated Protein that Suppresses Antiviral Responses in Cells
888800000094 10.1101/2020.08.13.249177 Carrique L (2020) The SARS-CoV-2 Spike harbours a lipid binding pocket which modulates stability of the prefusion trimer
888800000095 10.1101/2020.08.13.248211 Baddock HT (2020) Characterisation of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification
888800000096 10.1101/2020.08.10.244525 Malla TN (2020) Ebselen Reacts with SARS Coronavirus-2 Main Protease Crystals
888800000097 10.1101/2020.08.11.244863 Pillon MC (2020) Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15
888800000098 10.1101/2020.08.12.247338 Wang C (2020) Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection
888800000099 10.1101/2020.08.14.251421 Wilamowski M (2020) Methylation of RNA Cap in SARS-CoV-2 captured by serial crystallography
888800000100 10.1101/2020.08.13.248872 Wei C (2020) SARS-CoV-2 manipulates the SR-B1-mediated HDL uptake pathway for its entry
888800000101 10.1101/2020.08.14.251207 Heaton BE (2020) SRSF protein kinases 1 and 2 are essential host factors for human coronaviruses including SARS-CoV-2
888800000103 10.1101/2020.08.09.242867 Gai J (2020) A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential
888800000104 10.1101/2020.09.03.282103 Samavarchi-Tehrani P (2020) A SARS-CoV-2 - host proximity interactome
888800000105 10.1101/2020.09.09.287508 Gu Y (2020) Interaction network of SARS-CoV-2 with host receptome through spike protein
888800000106 10.1101/2020.08.29.273441 Bojadzic D (2020) Methylene Blue Inhibits In Vitro the SARS-CoV-2 Spike - ACE2 Protein-Protein Interaction - A Mechanism That Can Contribute to Its Antiviral Activity Against COVID-19
888800000107 10.1101/2020.09.04.282558 Bouwman KM (2020) Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins
888800000108 10.1101/2020.08.28.271601 Dash P (2020) Sequence analysis of Indian SARS-CoV-2 isolates shows a stronger interaction of mutated receptor binding domain with ACE2 receptor
888800000109 10.1101/2020.08.28.269175 St-Germain JR (2020) A SARS-CoV-2 BioID-based virus-host membrane protein interactome and virus peptide compendium: new proteomics resources for COVID-19 research
888800000111 10.1101/2020.09.04.280081 Qiang X (2020) Monoclonal Antibodies Capable of Binding SARS-CoV-2 Spike Protein Receptor Binding Motif Specifically Prevent GM-CSF Induction.
888800000112 10.1101/2020.09.09.287987 Durdagi S (2020) Near-Physiological-Temperature Serial Femtosecond X-ray Crystallography Reveals Novel Conformations of SARS-CoV-2 Main Protease Active Site for Improved Drug Repurposing
888800000113 10.1101/2020.09.01.277954 Bartolome A (2020) Angiotensin converting enzyme 2 is a novel target of the secretase complex
888800000115 10.1101/2020.09.09.289488 Kotani N (2020) Candidate screening of host cell membrane proteins involved in SARS-CoV-2 entry
888800000116 10.1101/2020.08.27.270637 Flower TG (2020) Structure of SARS-CoV-2 ORF8, a rapidly evolving coronavirus protein implicated in immune evasion
888800000117 10.1101/2020.09.21.307439 Wang X (2020) Bat and pangolin coronavirus spike glycoprotein structures provide insights into SARS-CoV-2 evolution
888800000118 10.1101/2020.09.14.295956 Lin C (2020) Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction
888800000119 10.1101/2020.09.16.297366 Sagar S (2020) Bromelain Inhibits SARS-CoV-2 Infection in VeroE6 Cells
888800000120 10.1101/2020.09.18.301952 Xiao T (2020) A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro
888800000121 10.1101/2020.09.16.297945 Meyer B (2020) Characterisation of protease activity during SARS-CoV-2 infection identifies novel viral cleavage sites and cellular targets for drug repurposing
888800000122 10.1101/2020.09.22.308338 Wagner TR (2020) NeutrobodyPlex - Nanobodies to monitor a SARS-CoV-2 neutralizing immune response
888800000123 10.1101/2020.09.20.297242 Ren W (2020) Comparative analysis reveals the species-specific genetic determinants of ACE2 required for SARS-CoV-2 entry
888800000124 10.1101/2020.09.13.295691 Olaleye OA (2020) Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein's Receptor Binding Domain and Recombinant Human ACE2.
888800000125 10.1101/2020.09.16.300319 Tada T (2020) A soluble ACE2 microbody protein fused to a single immunoglobulin Fc domain is a potent inhibitor of SARS-CoV-2 infection in cell culture
888800000126 10.1101/2020.09.16.299891 Higuchi Y (2020) High affinity modified ACE2 receptors prevent SARS-CoV-2 infection
888800000127 10.1101/2020.09.16.20190694 Ichimura T (2020) KIM-1/TIM-1 is a Receptor for SARS-CoV-2 in Lung and Kidney
888800000128 10.1101/2020.11.04.361154 de Vries (2020) Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets
888800000129 10.1101/2020.10.13.336800 Yan R (2020) Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies
888800000130 10.1101/2020.09.27.315796 Bauer MS (2020) A Tethered Ligand Assay to Probe the SARS-CoV-2 ACE2 Interaction under Constant Force
888800000131 10.1101/2020.10.06.328112 Lutomski CA (2020) Autoproteolytic Products of the SARS-CoV-2 Nucleocapsid Protein are Primed for Antibody Evasion and Virus Proliferation
888800000132 10.1101/2020.10.31.363473 Stevens BR (2020) TMPRSS2 and ADAM17 interactions with ACE2 complexed with SARS-CoV-2 and B0AT1 putatively in intestine, cardiomyocytes, and kidney
888800000133 10.1101/2020.10.23.350348 Tang X (2020) Transferrin receptor is another receptor for SARS-CoV-2 entry
888800000134 10.1101/2020.11.04.361576 Li W (2020) Human Identical Sequences of SARS-CoV-2 Promote Clinical Progression of COVID-19 by Upregulating Hyaluronan via NamiRNA-Enhancer Network
888800000135 10.1101/2020.10.29.352450 Bakovic A (2020) Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2
888800000136 10.1101/2020.10.26.356048 Liu G (2020) ISG15-dependent Activation of the RNA Sensor MDA5 and its Antagonism by the SARS-CoV-2 papain-like protease
888800000137 10.1101/2020.10.16.342097 Gao X (2020) Duple extinguishment of COVID-19: single compound synergized inhibition of SARS-CoV-2 replication and direct suppression of inflammatory cytokines in vitro/vivo
888800000138 10.1101/2020.10.13.337584 Roy A (2020) ACIS, A Novel KepTide(tm), Binds to ACE-2 Receptor and Inhibits the Infection of SARS-CoV2 Virus in vitro in Primate Kidney Cells: Therapeutic Implications for COVID-19
888800000139 10.1101/2020.10.30.361873 Andring JT (2020) Amino acid transporter B0AT1 influence on ADAM17 interactions with SARS-CoV-2 receptor ACE2 putatively expressed in intestine, kidney, and cardiomyocytes
888800000140 10.1101/2020.10.23.347534 Mellott D (2020) A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells
888800000141 10.1101/2020.10.06.327742 Kliche J (2020) Cytoplasmic short linear motifs in ACE2 and integrin beta3 link SARS-CoV-2 host cell receptors to endocytosis and autophagy
888800000142 10.1101/2020.10.18.344622 Chan KK (2020) An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants
888800000143 10.1101/2020.11.01.363788 Sun J (2020) Discovery of five HIV nucleoside analog reverse-transcriptase inhibitors (NRTIs) as potent inhibitors against the RNA-dependent RNA polymerase (RdRp) of SARS-CoV and 2019-nCoV
888800000144 10.1101/2020.10.30.362335 Hu Y (2020) Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture
888800000145 10.1101/2020.10.11.335299 Gobeil S (2020) D614G mutation alters SARS-CoV-2 spike conformational dynamics and protease cleavage susceptibility at the S1/S2 junction
888800000146 10.1101/2020.10.06.327445 Flynn RA (2020) Systematic discovery and functional interrogation of SARS-CoV-2 viral RNA-host protein interactions during infection
888800000147 10.1101/2020.09.24.312553 Li Y (2020) SARS-CoV-2 induces double-stranded RNA-mediated innate immune responses in respiratory epithelial derived cells and cardiomyocytes
888800000148 10.1101/2020.10.22.351569 Nguyen HT (2020) Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects
888800000149 10.1101/2020.10.22.351056 Bojadzic D (2020) Small-Molecule In Vitro Inhibitors of the Coronavirus Spike - ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2
888800000150 10.1101/2020.10.08.20209114 Wu F (2020) Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis
888800000151 10.1101/2020.09.30.317818 Hsu AC-Y (2020) SARS-CoV-2 Spike protein promotes hyper-inflammatory response that can be ameliorated by Spike-antagonistic peptide and FDA-approved ER stress and MAP kinase inhibitors in vitro
888800000152 10.1101/2020.11.05.369264 Soh WT (2020) The N-terminal domain of spike glycoprotein mediates SARS-CoV-2 infection by associating with L-SIGN and DC-SIGN
888800000153 10.1101/2020.12.02.408153 Roth A (2020) LL-37 fights SARS-CoV-2: The Vitamin D-Inducible Peptide LL-37 Inhibits Binding of SARS-CoV-2 Spike Protein to its Cellular Receptor Angiotensin Converting Enzyme 2 In Vitro
888800000154 10.1101/2020.11.24.20237628 Al Ahmad M (2020) Development of an Optical Assay to Detect SARS-CoV-2 Spike Protein Binding Interactions with ACE2 and Disruption of these Interactions Using Electric Current
888800000155 10.1101/2020.12.06.413443 Svilenov HL (2020) Efficient inhibition of SARS-CoV-2 strains by a novel ACE2-IgG4-Fc fusion protein with a stabilized hinge region
888800000156 10.1101/2020.12.01.406116 Tito A (2020) A pomegranate peel extract as inhibitor of SARS-CoV-2 Spike binding to human ACE2 (in vitro): a promising source of novel antiviral drugs
888800000157 10.1101/2020.11.24.393629 Wang X (2020) Double Lock of a Potent Human Monoclonal Antibody against SARS-CoV-2
888800000158 10.1101/2020.12.03.409441 Rossetti GG (2020) Identification of low micromolar SARS-CoV-2 Mpro inhibitors from hits identified by in silico screens
888800000159 10.1101/2020.11.11.378018 Eberle RJ (2020) The repurposed drugs suramin and quinacrine inhibit cooperatively in vitro SARS-CoV-2 3CLpro
888800000160 10.1101/2020.11.12.378422 Guenther S (2020) Inhibition of SARS-CoV-2 main protease by allosteric drug-binding
888800000161 10.1101/2020.12.06.412759 Calistri A (2020) The new generation hDHODH inhibitor MEDS433 hinders the in vitro replication of SARS-CoV-2
888800000162 10.1101/2020.12.03.409318 Bertoglio F (2020) A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations
888800000163 10.1101/2020.11.06.368191 Kraus A (2020) A zebrafish model for COVID-19 recapitulates olfactory and cardiovascular pathophysiologies caused by SARS-CoV-2
888800000164 10.1101/2020.12.23.424149 Noske G (2020) A Crystallographic Snapshot of SARS-CoV-2 Main Protease Maturation Process
888800000165 10.1101/2020.12.18.423427 Zhao Y (2020) SARS-CoV-2 spike protein interacts with and activates TLR4
888800000166 10.1101/2020.12.19.423537 Kitamura N (2020) An expedited approach towards the rationale design of non-covalent SARS-CoV-2 main protease inhibitors with in vitro antiviral activity
888800000167 10.1101/2020.12.23.424171 Schmitz A (2020) A SARS-CoV-2 spike binding DNA aptamer that inhibits pseudovirus infection in vitro by an RBD independent mechanism
888800000168 10.1101/2020.12.31.424961 Chen Z (2021) Comprehensive analysis of the host-virus interactome of SARS-CoV-2
888800000169 10.1101/2020.12.21.423721 Avolio E (2020) The SARS-CoV-2 spike protein disrupts the cooperative function of human cardiac pericytes - endothelial cells through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease
888800000170 10.1101/2020.12.19.423584 Garcia-Dorival I (2020) Identification of NPC1 as a novel SARS-CoV-2 intracellular target
888800000171 10.1101/2020.12.26.424423 Durdagi S (2020) The neutralization effect of Montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies
888800000172 10.1101/2020.12.18.423415 Madan T (2020) A recombinant fragment of Human surfactant protein D binds Spike protein and inhibits infectivity and replication of SARS-CoV-2 in clinical samples
888800000173 10.1101/2020.12.29.424698 Yang X (2020) An Ultrasensitive Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and in vitro
888800000174 10.1101/2020.12.20.422820 Fiedler S (2020) In vitro measurements of protein-protein interactions show that antibody affinity governs the inhibition of SARS-CoV-2 spike/ACE2 binding in convalescent serum
888800000175 10.1101/2020.12.22.422708 Shepley-McTaggart A (2020) SARS-CoV-2 Envelope (E) Protein Interacts with PDZ-Domain-2 of Host Tight Junction Protein ZO1
888800000176 10.1101/2020.12.18.423418 Hsieh M-H (2020) Human Surfactant Protein D Binds S1 and Receptor Binding Domain of Spike protein and acts as an entry inhibitor of SARS-CoV-2 Pseudotyped viral particles in vitro
888800000177 10.1101/2020.12.16.422677 Kuzikov M (2020) Identification of inhibitors of SARS-CoV-2 3CL-Pro enzymatic activity using a small molecule in-vitro repurposing screen
888800000178 10.1101/2020.12.30.424801 Woo HG (2020) Pharmacophore-based peptide biologics neutralize SARS-CoV-2 S1 and deter S1-ACE2 interaction in vitro
888800000179 10.1101/2020.12.26.424422 Xu W (2020) Extensive High-Order Complexes within SARS-CoV-2 Proteome Revealed by Compartmentalization-Aided Interaction Screening
888800000180 10.1101/2020.12.09.417741 Armstrong L (2020) Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies
888800000181 10.1101/2020.12.29.424682 Kuznetsov A (2020) ACE2 peptide fragment interacts with several sites on the SARS-CoV-2 spike protein S1
888800000182 10.1101/2021.01.21.427657 Choi R (2021) High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity.
888800000183 10.1101/2021.01.12.426388 Kneller DW (2021) Inhibitor Binding Modulates Protonation States in the Active Site of SARS-CoV-2 Main Protease
888800000184 10.1101/2021.01.17.427000 Wan Y (2021) Comprehensive mapping of SARS-CoV-2 interactions in vivo reveals functional virus-host interactions
888800000185 10.1101/2021.01.19.427194 Tian R (2021) BRD2 inhibition blocks SARS-CoV-2 infection in vitro by reducing transcription of the host cell receptor ACE2
888800000186 10.1101/2021.01.11.426269 Zhu X (2021) Cryo-EM Structure of the N501Y SARS-CoV-2 Spike Protein in Complex with a Potent Neutralizing Antibody
888800000187 10.1101/2021.01.05.425478 Kamle S (2021) Chitinase 3-like-1 is a Therapeutic Target That Mediates the Effects of Aging in COVID-19
888800000188 10.1101/2021.01.14.426695 Carnell GW (2021) SARS-CoV-2 spike protein arrested in the closed state induces potent neutralizing responses
888800000189 10.1101/2021.01.13.21249429 Hultstrom M (2021) Elevated Angiopoietin-2 inhibits thrombomodulin-mediated anticoagulation in critically ill COVID-19 patients
888800000190 10.1101/2021.01.19.427324 Suryadevara N (2021) Neutralizing and protective human monoclonal antibodies recognizing the N-terminaldomain of the SARS-CoV-2 spike protein
888800000191 10.1101/2021.01.11.426218 Rapp M (2021) Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class
888800000192 10.1101/2021.01.07.425745 Saramago M (2021) New targets for drug design: Importance of nsp14/nsp10 complex formation for the 3'-5' exoribonucleolytic activity on SARS-CoV-2
888800000193 10.1101/2021.01.12.426042 Siniavin AE (2021) Snake venom phospholipases A2 possess a strong virucidal activity against SARS-CoV-2 in vitro and block the cell fusion mediated by spike glycoprotein interaction with the ACE2 receptor
888800000194 10.1101/2021.01.07.425806 Bell BN (2021) Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naive human antibody library
888800000195 10.1101/2021.01.20.427368 Carlos AJ (2021) GRP78 binds SARS-CoV-2 Spike protein and ACE2 and GRP78 depleting antibody blocks viral entry and infection in vitro
888800000196 10.1101/2021.01.05.425516 Verma R (2021) RNA-protein interaction analysis of SARS-CoV-2 5'- and 3'-untranslated regions identifies an antiviral role of lysosome-associated membrane protein-2
888800000197 10.1101/2021.01.29.428890 Berndt AJ (2021) Recombinant production of a functional SARS-CoV-2 spike receptor binding domain in the green algae Chlamydomonas reinhardtii
888800000198 10.1101/2021.01.29.428834 Bayarri-Olmos R (2021) The SARS-CoV-2 Y453F mink variant displays a striking increase in ACE-2 affinity but does not challenge antibody neutralization
888800000199 10.1101/2021.02.03.429601 Prahlad J (2021) Bacterial expression and purification of functional recombinant SARS-CoV-2 spike receptor binding domain
888800000200 10.1101/2021.02.03.429625 Khalili Yazdi A (2021) A high-throughput radioactivity-based assay for screening SARS-CoV-2 nsp10-nsp16 complex
888800000201 10.1101/2021.02.01.429176 Caillet-Saguy C (2021) Host PDZ-containing proteins targeted by SARS-Cov-2
888800000202 10.1101/2021.02.11.430866 Liu H (2021) A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
888800000203 10.1101/2021.02.02.429311 Ma H (2021) Potent in vitro Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain
888800000204 10.1101/2021.02.19.424337 Devkota K (2021) Probing the SAM Binding Site of SARS-CoV-2 nsp14 in vitro Using SAM Competitive Inhibitors Guides Developing Selective bi-substrate Inhibitors
888800000205 10.1101/2021.02.13.431008 Shen Z (2021) Potent, Novel SARS-CoV-2 PLpro Inhibitors Block Viral Replication in Monkey and Human Cell Cultures
888800000206 10.1101/2021.02.17.431617 Bollavaram K (2021) Multiple Sites on SARS-CoV-2 Spike Protein are Susceptible to Proteolysis by Cathepsins B, K, L, S, and V
888800000207 10.1101/2021.01.31.429023 Minasov G (2021) Mn2+ coordinates Cap-0-RNA to align substrates for efficient 2'-O-methyl transfer by SARS-CoV-2 nsp16
888800000208 10.1101/2021.02.03.429355 Graham C (2021) Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike
888800000209 10.1101/2021.02.09.430451 Spelios MG (2021) A novel antibody against the furin cleavage site of SARS-CoV-2 spike protein: effects on proteolytic cleavage and ACE2 binding
888800000210 10.1101/2021.02.02.428884 Zhang G (2021) The basis of a more contagious 501Y.V1 variant of SARS-COV-2
888800000211 10.1101/2021.02.16.431021 Arutyunova E (2021) N-Terminal finger stabilizes the reversible feline drug GC376 in SARS-CoV-2 Mpro
888800000212 10.1101/2021.02.07.429299 Gu C (2021) A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus macaques
888800000213 10.1101/2021.02.04.429751 Slavin M (2021) Targeted in situ cross-linking mass spectrometry and integrative modeling reveal the architectures of Nsp1, Nsp2, and Nucleocapsid proteins from SARS-CoV-2
888800000214 10.1101/2021.02.08.430344 Zhao H (2021) Energetic and structural features of SARS-CoV-2 N-protein co-assemblies with nucleic acids
888800000215 10.1101/2021.02.14.431117 Tian F (2021) Mutation N501Y in RBD of Spike Protein Strengthens the Interaction between COVID-19 and its Receptor ACE2
888800000216 10.1101/2021.02.17.431755 Zhao Y (2021) SARS-CoV-2 nucleocapsid protein dually regulates innate immune responses
covid/unpublished.txt · Last modified: 2021/04/24 15:17 by biogridadmin